Presentation is loading. Please wait.

Presentation is loading. Please wait.

High SUVmax on FDG-PET Indicates Pleomorphic Subtype in Epithelioid Malignant Pleural Mesothelioma: Supportive Evidence to Reclassify Pleomorphic as Nonepithelioid.

Published byGrace Chapman Modified over 5 years ago

Similar presentations

Presentation on theme: "High SUVmax on FDG-PET Indicates Pleomorphic Subtype in Epithelioid Malignant Pleural Mesothelioma: Supportive Evidence to Reclassify Pleomorphic as Nonepithelioid."— Presentation transcript:

1 High SUVmax on FDG-PET Indicates Pleomorphic Subtype in Epithelioid Malignant Pleural Mesothelioma: Supportive Evidence to Reclassify Pleomorphic as Nonepithelioid Histology  Kyuichi Kadota, MD, PhD, Stefan S. Kachala, MD, Jun-ichi Nitadori, MD, PhD, Kei Suzuki, MD, Mark P.S. Dunphy, DO, Camelia S. Sima, MD, MS, William D. Travis, MD, Valerie W. Rusch, MD, Prasad S. Adusumilli, MD  Journal of Thoracic Oncology  Volume 7, Issue 7, Pages (July 2012) DOI: /JTO.0b013e d96 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Overall survival (OS) and time to recurrence (TTR) by maximum standardized uptake value (SUVmax). A, The median OS of patients with epithelioid tumors with high SUVmax (n = 12) was significantly shorter (7.1 months) than that of patients with epithelioid tumors with low SUVmax (n = 54, 18.9 months) and comparable to patients with nonepithelioid tumors (n = 12, 7.2 months). B, In 44 patients with completely resected epithelioid tumors, the median TTR for those with high SUVmax (n = 7) was significantly shorter (14.4 months) than that of patients with low SUVmax (n = 37, 21.9 months). SUVmax, maximum standardized uptake value. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e d96) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Association between maximum standardized uptake value (SUVmax) and histology. A, Within the epithelioid tumors, pleomorphic subtype (n = 9) had the highest SUVmax (mean ± SD: 10.6 ± 5.9), followed by solid (n = 20, 6.5 ± 2.9), micropapillary (n = 10, 6.1 ± 2.8), tubulopapillary (n = 18, 6.7 ± 4.0), and trabecular (n = 9, 6.7 ± 3.0). B, SUVmax of nonepithelioid tumors (n = 12, 9.1 ± 4.8) was similar to that of pleomorphic subtype and significantly higher than that of epithelioid nonpleomorphic subtype (n = 57, 6.5 ± 3.2). SUVmax, maximum standardized uptake value. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e d96) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "High SUVmax on FDG-PET Indicates Pleomorphic Subtype in Epithelioid Malignant Pleural Mesothelioma: Supportive Evidence to Reclassify Pleomorphic as Nonepithelioid."

Similar presentations

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center  Raja M. Flores, MD, Maureen Zakowski, MD, Ennapadam.

Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center  Raja M. Flores, MD, Maureen Zakowski, MD, Ennapadam.
Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related.

Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related.
Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic.

Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic.
Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer–Specific Death in Squamous Cell Carcinoma  Shaohua Lu, MD,

Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer–Specific Death in Squamous Cell Carcinoma  Shaohua Lu, MD,
Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 
Usman Ahmad, MD, Haoxian Yang, MD, Camelia Sima, MD, MS, Daniel H

Usman Ahmad, MD, Haoxian Yang, MD, Camelia Sima, MD, MS, Daniel H
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.

Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.
Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases  Åslaug Helland, MD, PhD, Steinar Solberg,

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases  Åslaug Helland, MD, PhD, Steinar Solberg,
Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C
Pleural Fluid Cytological Yield and Visceral Pleural Invasion in Patients with Epithelioid Malignant Pleural Mesothelioma  Valentina Pinelli, MD, Sophie.

Pleural Fluid Cytological Yield and Visceral Pleural Invasion in Patients with Epithelioid Malignant Pleural Mesothelioma  Valentina Pinelli, MD, Sophie.
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
MA12.06 Tumor Spread through Air Spaces (STAS) in Lung Squamous Cell Cancer is an Independent Risk Factor: A Competing Risk Analysis  Shaohua Lu, Takashi.

MA12.06 Tumor Spread through Air Spaces (STAS) in Lung Squamous Cell Cancer is an Independent Risk Factor: A Competing Risk Analysis  Shaohua Lu, Takashi.
DNA Repair Polymorphisms and Treatment Outcomes of Patients with Malignant Mesothelioma Treated with Gemcitabine-Platinum Combination Chemotherapy  Nina.

DNA Repair Polymorphisms and Treatment Outcomes of Patients with Malignant Mesothelioma Treated with Gemcitabine-Platinum Combination Chemotherapy  Nina.
A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma  Isabelle Opitz, MD, Martina Friess,

A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma  Isabelle Opitz, MD, Martina Friess,
MA12.09 Comparative Histological Subtype Analysis of Lung Adenocarcinoma Tumor and Metastatic Lymph Nodes and the Prognostic Impact  Shaohua Lu, Takashi.

MA12.09 Comparative Histological Subtype Analysis of Lung Adenocarcinoma Tumor and Metastatic Lymph Nodes and the Prognostic Impact  Shaohua Lu, Takashi.
Risk stratification for lung nodules: Size isn't everything

Risk stratification for lung nodules: Size isn't everything
Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma  Ho Yun Lee, MD, PhD, So Won Lee, MD, Kyung.

Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma  Ho Yun Lee, MD, PhD, So Won Lee, MD, Kyung.
An Unusual Presentation of Malignant Pleural Mesothelioma

An Unusual Presentation of Malignant Pleural Mesothelioma
Pleomorphic Epithelioid Diffuse Malignant Pleural Mesothelioma: A Clinicopathological Review and Conceptual Proposal to Reclassify as Biphasic or Sarcomatoid.

Pleomorphic Epithelioid Diffuse Malignant Pleural Mesothelioma: A Clinicopathological Review and Conceptual Proposal to Reclassify as Biphasic or Sarcomatoid.

Similar presentations

Ads by Google